Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors
Andrew L. Lin,Vasilisa A. Rudneva,Allison L. Richards,Yanming Zhang,Hyung Jun Woo,Marc Cohen,Jamie Tisnado,Nazanin Majd,Sharon L. Wardlaw,Gabrielle Page-Wilson,Soma Sengupta,Frances Chow,Bernard Goichot,Byram H. Ozer,Jorg Dietrich,Lisa Nachtigall,Arati Desai,Tina Alano,Shahiba Ogilive,David B. Solit,Tejus A. Bale,Marc Rosenblum,Mark T. A. Donoghue,Eliza B. Geer,Viviane Tabar
DOI: https://doi.org/10.1007/s00401-024-02736-8
IF: 15.887
2024-05-19
Acta Neuropathologica
Abstract:Pituitary neuroendocrine tumors (PitNETs) exhibiting aggressive, treatment-refractory behavior are the rare subset that progress after surgery, conventional medical therapies, and an initial course of radiation and are characterized by unrelenting growth and/or metastatic dissemination. Two groups of patients with PitNETs were sequenced: a prospective group of patients ( n = 66) who consented to sequencing prior to surgery and a retrospective group ( n = 26) comprised of aggressive/higher risk PitNETs. A higher mutational burden and fraction of loss of heterozygosity (LOH) was found in the aggressive, treatment-refractory PitNETs compared to the benign tumors ( p = 1.3 × 10 −10 and p = 8.5 × 10 −9 , respectively). Within the corticotroph lineage, a characteristic pattern of recurrent chromosomal LOH in 12 specific chromosomes was associated with treatment-refractoriness (occurring in 11 of 14 treatment-refractory versus 1 of 14 benign corticotroph PitNETs, p = 1.7 × 10 −4 ). Across the cohort, a higher fraction of LOH was identified in tumors with TP53 mutations ( p = 3.3 × 10 −8 ). A machine learning approach identified loss of heterozygosity as the most predictive variable for aggressive, treatment-refractory behavior, outperforming the most common gene-level alteration, TP53 , with an accuracy of 0.88 (95% CI: 0.70–0.96). Aggressive, treatment-refractory PitNETs are characterized by significant aneuploidy due to widespread chromosomal LOH, most prominently in the corticotroph tumors. This LOH predicts treatment-refractoriness with high accuracy and represents a novel biomarker for this poorly defined PitNET category.
pathology,neurosciences,clinical neurology